Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch

Molecular Imaging

Volumn 6, Issue 6, 2007, Pages 393-403

  Lepage, Martin ^a   Dow, William C ^b   Melchior, Marco ^b   You, Ying ^b   Fingleton, Barbara ^b   Quarles, C Chad ^b   Pépin, Claude ^b   Gore, John C ^b   Matrisian, Lynn M ^b   McIntyre, J Oliver ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; NONINVASIVE DETECTION; SOLUBILITY SWITCH;

ENZYME ACTIVITY; HYDROPHILICITY; HYDROPHOBICITY; MAGNETIC RESONANCE IMAGING; PHARMACOKINETICS;

PROTEINS;

CONTRAST MEDIUM; MATRILYSIN; MATRIX METALLOPROTEINASE;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; EVALUATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; SOLUBILITY;

ANIMALS; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 37649020428     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2007.00035     Document Type: Article

References (34)

1. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
2. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-92.
3. Overall CM, Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
4. Sprague JE, Ping Li W, Liang K, et al. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol 2006;33:227-37.
5. Tóth É, Helm L, Merbach AE. Relaxivity of gadolinium(III) complexes: theory and mechanism. In: Merbach AE, Tóth E, editors. The chemistry of contrast agents in medical magnetic resonance imaging. Chichester (UK): John Wiley & Sons; 2001. p. 45-119.
6. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17:509-20.
7. Weinmann HJ, Laniado M, Mützel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167-72.
8. Henderson E, Sykes J, Drost D, et al. Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents. J Magn Reson Imaging 2000;12:991-1003.
9. Lüdemann L, Hamm B, Zimmer C. Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magn Reson Imaging 2000;18:1201-14.
10. Fritz-Hansen T, Rostrup E, Larsson HBW, et al. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med 1996;36:225-31.
11. Furman-Haran E, Margalit R, Grobgeld D, Degani H. Dynamic contrast-enhanced magnetic resonance imaging reveals stressinduced angiogenesis in MCF7 human breast tumors. Proc Natl Acad Sci U S A 1996;93:6247-51.
12. Gore JC, Kennan RP. Contrast agents and relaxation effects. In: Atlas SW, editor. Magnetic resonance imaging of the brain and spine. Philadelphia: Lippincott-Raven; 1996. p. 89-107.
13. Heckl S, Debus J, Jenne J, et al. CNN-Gd3+ enables cell nucleus molecular imaging of prostate cancer cells: the last 600 nm. Cancer Res 2002;62:7018-24.
14. Wiener EC, Konda S, Shadron A, et al. Targeting dendrimerchelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol 1997;32:748-54.
15. Louie AY, Hüber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000;18:321-5.
16. Frullano L, Tejerina B, Meade TJ. Synthesis and characterization of a doxorubicin-Gd(III) contrast agent conjugate: a new approach toward prodrug-procontrast complexes. Inorg Chem 2006;45: 8489-91.
17. Wilson CL, Matrisian LM. Matrilysin. In: Parks WC, Mecham RP, editors. Matrix metalloproteinases. San Diego: Academic Press; 1998. p. 149-84.
18. Welch AR, Holman CM, Huber M, et al. Understanding the P-I' specificity of the matrix metalloproteinases: effect of S-I' pocket mutations in matrilysin and stromelysin-1. Biochemistry 1996;35: 10103-9.
19. Witty JP, McDonnell S, Newell K, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo, Cancer Res 1994;54:4805-12.
20. Murry PJ, Baldock C. Research software for radiotherapy gel dosimetry. Australas Phys Eng Sci Med 2000;23:44-51.
21. Welch AR, Holman CM, Browner MF, et al. Purification of human matrylisin produced by Escherichia coli and characterization using a new optimized fluorogenic peptide substrate. Arch Biochem Biophys 1995;324:59-64.
22. Mclntyre JO, Fingleton B, Wells KS, et al. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J 2004;377:617-28.
23. Checkley D, Tessier JJL, Wedge SR, et al. Dynamic contrastenhanced MRI of vascular changes induced by the VEGF-signaling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging 2003;21:475-82.
24. Bhujwalla ZM, Artemov D, Natarajan K, et al. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 2001;3:143-53.
25. Lyng H, Dahle GA, Kaalhus O, et al. Measurement of perfusion rate in human melanoma xenografts by contrastenhanced magnetic resonance imaging. Magn Reson Med 1998; 40:89-98.
26. Yankeelov TE, Luci JJ, Lepage M, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 2005;23: 519-29.
27. Mollica F, Jain RK, Nettie PA. A model for temporal heterogeneities of tumor blood flow. Microvasc Res 2003;65:5660.
28. Su M-Y, Cheung Y-C, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003;18:467-77.
29. Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrastenhanced perfusion MRI in mouse gliomas: correlation with histopathology Magn Reson Med 2003;49:848-55.
30. Giambernardi TA, Grant GM, Taylor GP, et al. Overview of matrix ' metalloproteinase expression in cultured human cells. Matrix Biol 1998;16:483-96.
31. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003;4:544-58.
32. Rawlings ND, Morton FR, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res 2006;l:D270-2.
33. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17: 7-30.
34. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 1992;31:71524.